🚀 VC round data is live in beta, check it out!
Organon Valuation Multiples
Discover revenue and EBITDA valuation multiples for Organon and similar public comparables like Natco Pharma, Tyra Biosciences, Pacific Shuanglin, Recursion Pharmaceuticals and more.
Organon Overview
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Founded
2020
HQ
Employees
10.0K
Website
Financials (LTM)
EV
$10B
Organon Financials
Organon reported last 12-month revenue of $6B and EBITDA of $2B.
In the same LTM period, Organon generated $4B in gross profit, $2B in EBITDA, and $941M in net income.
Revenue (LTM)
Organon P&L
In the most recent fiscal year, Organon reported revenue of $6B and EBITDA of $2B.
Organon expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6B | XXX | $6B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $941M | XXX | $954M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | — | — | $8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Organon Stock Performance
Organon has current market cap of $2B, and enterprise value of $10B.
Market Cap Evolution
Organon's stock price is $7.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $2B | 0.0% | XXX | XXX | XXX | $3.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrganon Valuation Multiples
Organon trades at 1.6x EV/Revenue multiple, and 5.2x EV/EBITDA.
EV / Revenue (LTM)
Organon Financial Valuation Multiples
As of March 30, 2026, Organon has market cap of $2B and EV of $10B.
Equity research analysts estimate Organon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Organon has a P/E ratio of 2.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBIT | 5.7x | XXX | 5.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | 3.0x | XXX | XXX | XXX |
| P/E | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/FCF | 17.7x | XXX | 19.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Organon Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Organon Margins & Growth Rates
Organon's revenue in the last 12 month declined by (0%).
Organon's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Organon's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organon's rule of X is 29% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Organon Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (0%) | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | (1%) | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Organon Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Tyra Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Shuanglin | XXX | XXX | XXX | XXX | XXX | XXX |
| Recursion Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Organon M&A Activity
Organon acquired XXX companies to date.
Last acquisition by Organon was on XXXXXXXX, XXXXX. Organon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Organon
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOrganon Investment Activity
Organon invested in XXX companies to date.
Organon made its latest investment on XXXXXXXX, XXXXX. Organon invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Organon
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Organon
| When was Organon founded? | Organon was founded in 2020. |
| Where is Organon headquartered? | Organon is headquartered in United States. |
| How many employees does Organon have? | As of today, Organon has over 10K employees. |
| Who is the CEO of Organon? | Organon's CEO is Joseph T. Morrissey. |
| Is Organon publicly listed? | Yes, Organon is a public company listed on NYSE. |
| What is the stock symbol of Organon? | Organon trades under OGN ticker. |
| When did Organon go public? | Organon went public in 2021. |
| Who are competitors of Organon? | Organon main competitors are Natco Pharma, Tyra Biosciences, Pacific Shuanglin, Recursion Pharmaceuticals. |
| What is the current market cap of Organon? | Organon's current market cap is $2B. |
| What is the current revenue of Organon? | Organon's last 12 months revenue is $6B. |
| What is the current revenue growth of Organon? | Organon revenue growth (NTM/LTM) is (0%). |
| What is the current EV/Revenue multiple of Organon? | Current revenue multiple of Organon is 1.6x. |
| Is Organon profitable? | Yes, Organon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organon? | Organon's last 12 months EBITDA is $2B. |
| What is Organon's EBITDA margin? | Organon's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Organon? | Current EBITDA multiple of Organon is 5.2x. |
| What is the current FCF of Organon? | Organon's last 12 months FCF is $563M. |
| What is Organon's FCF margin? | Organon's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Organon? | Current FCF multiple of Organon is 17.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.